Retraction: Alpinetin suppresses proliferation of human hepatoma cells by the activation of MKK7 and elevates sensitization to cis-diammined dichloridoplatium (Oncology Reports (2012) 27 (1090-1096) DOI: 10.3892/or.2011.1580);Alpinetin suppresses proliferation of human hepatoma cells by the activation of MKK7 and elevates sensitization to cis-diammined dichloridoplatium

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 1090-1096

  Tang, Bo ^a   Du, Jian ^a   Wang, Jingwen ^b   Tan, Guang ^a   Gao, Zhenming ^a   Wang, Zhongyu ^a   Wang, Liming ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alpinetin; Cis diammined dichloridoplatium; Hepatocellular carcinoma; MKK7; Proliferation

Indexed keywords

ALPINETIN; ANTINEOPLASTIC AGENT; CIS DIAMMINED DICHLORIDOPLATINUM; MITOGEN ACTIVATED PROTEIN KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE 7; PLATINUM DERIVATIVE; RNA; TETRAZOLIUM; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

EID: 84863071273     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2023.8534     Document Type: Erratum

References (37)

1. Rampone B, Schiavone B, Martino A, Viviano C and Confuorto G: Current management strategy of hepatocellular carcinoma. World J Gastroenterol 15: 3210-3216, 2009.
2. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
3. Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253: 453-469, 2011.
4. Merle P and Mornex F: Medical therapies for hepatocellular carcinoma. Cancer Radiother 15: 28-31, 2011.
5. Llovet JM, Fuster J and Bruix J: The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10: S115-S120, 2004. (Pubitemid 38240111)
6. Vogel S, Ohmayer S, Brunner G and Heilmann J: Natural and non-natural prenylated chalcones: synthesis, cytotoxicity and anti-oxidative activity. Bioorg Med Chem 16: 4286-4293, 2008. (Pubitemid 351539046)
7. Tang J, Li N, Dai H and Wang K: Chemical constituents from seeds of Alpinia katsumadai, inhibition on NF-kappaB activation and anti-tumor effect. Zhongguo Zhong Yao Za Zhi 35: 1710-1714, 2010.
8. He W, Li Y, Tang J, Luan F, Jin J and Hu Z: Comparison of the characterization on binding of alpinetin and cardamonin to lysozyme by spectroscopic methods. Int J Biol Macromol 39: 165-173, 2006. (Pubitemid 44602201)
9. Wang S, Zhou L, He W and Hu Z: Separation and determination of alpinetin and cardamonin by reverse micelle electrokinetic capillary chromatography. J Pharm Biomed Anal 43: 1557-1561, 2007. (Pubitemid 46282395)
10. Malek SN, Phang CW, Ibrahim H, Norhanom AW and Sim KS: Phytochemical and cytotoxic investigations of Alpinia mutica rhizomes. Molecules 16: 583-589, 2011.
11. In LL, Azmi MN, Ibrahim H, Awang K and Nagoor NH: 1′S-1′- acetoxyeugenol acetate: a novel phenylpropanoid from Alpinia conchigera enhances the apoptotic effects of paclitaxel in MCF-7 cells through NF-κB inactivation. Anticancer Drugs 22: 424-434, 2011.
12. He ZH, Ge W, Yue GG, Lau CB, He MF and But PP: Anti-angiogenic effects of the fruit of Alpinia oxyphylla. J Ethnopharmacol 132: 443-449, 2010.
13. Suzuki A, Guicheux J, Palmer G, Miura Y, Oiso Y, Bonjour JP and Caverzasio J: Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase during osteoblastic cell differentiation. Bone 30: 91-98, 2002. (Pubitemid 34044306)
14. Molton SA, Todd DE and Cook SJ: Selective activation of the c-Jun N-terminal kinase (JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3′-kinase (PI3K) pathway is inhibited. Oncogene 22: 4690-4701, 2003. (Pubitemid 36976444)
15. Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001. (Pubitemid 32225829)
16. Dérijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ and Davis RJ: Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267: 682-685,1995.
17. Kishimoto H, Nakagawa K, Watanabe T, Kitagawa D, Momose H, Seo J, Nishitai G, Shimizu N, Ohata S, Tanemura S, Asaka S, Goto T, Fukushi H, Yoshida H, Suzuki A, Sasaki T, Wada T, Penninger JM, Nishina H and Katada T: Different properties of SEK1 and MKK7 in dual phosphorylation of stress-induced activated protein kinase SAPK/JNK in embryonic stem cells. J Biol Chem 278: 16595-16601, 2003. (Pubitemid 36799521)
18. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA and Davis RJ: MKK7is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 15: 1419-1426, 2001. (Pubitemid 32524648)
19. Finch A, Holland P, Cooper J, Saklatvala J and Kracht M: Selective activation of JNK/SAPK by interleukin-1 in rabbit liver is mediated by MKK7. FEBS Lett 418: 144-148, 1997. (Pubitemid 27514434)
20. Wang X, Destrument A and Tournier C: Physiological roles of MKK4 and MKK7: insights from animal models. Biochim Biophys Acta 1773: 1349-1357, 2007. (Pubitemid 47125970)
21. Choi JE, Hur W, Jung CK, Piao LS, Lyoo K, Hong SW, Kim SW, Yoon HY and Yoon SK: Silencing of 14-3-3ζ over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium. Cancer Lett 303: 99-107, 2011.
22. Raman M, Chen W and Cobb MH: Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112, 2007. (Pubitemid 46763006)
23. Saito H: Regulation of cross-talk in yeast MAPK signaling pathways. Curr Opin Microbiol 13: 677-683, 2010.
24. Galeotti N and Ghelardini C: Regionally selective activation and differential regulation of ERK, JNK and p38 MAP kinase signalling pathway by protein kinase C in mood modulation. Int J Neuropsychopharmacol 20: 1-13, 2011.
25. Huang P, Han J and Hui L: MAPK signaling in inflammation-associated cancer development. Protein Cell 1: 218-226, 2010.
26. Bermudez O, Pagès G and Gimond C: The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol 299: C189-C202, 2010.
27. Haeusgen W, Herdegen T and Waetzig V: The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7. Eur J Cell Biol 90: 536-544, 2011.
28. Hammaker DR, Boyle DL, Inoue T and Firestein GS: Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes. Arthritis Res Ther 9: R57, 2007.
29. Tu Z, Mooney SM and Lee FS: A subdomain of MEKK1 that is critical for binding to MKK4. Cell Signal 15: 65-77, 2003. (Pubitemid 35223630)
30. Zhang Q, Tian H, Fu X and Zhang G: Delayed activation and regulation of MKK7 in hippocampal CA1 region following global cerebral ischemia in rats. Life Sci 74: 37-45, 2003. (Pubitemid 37324218)
31. Takekawa M, Tatebayashi K and Saito H: Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol Cell 18: 295-306, 2005. (Pubitemid 41350535)
32. Mooney LM and Whitmarsh AJ: Docking interactions in the c-Jun N-terminal kinase pathway. J Biol Chem 279: 11843-11852, 2003.
33. Mondal S, Mandal C, Sangwan R, Chandra S and Mandal C: Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol Cancer 9: 239, 2010.
34. Yang MD, Lai KC, Lai TY, Hsu SC, Kuo CL, Yu CS, Lin ML, Yang JS, Kuo HM, Wu SH and Chung JG: Phenethyl isothiocyanate inhibits migration and invasion of human gastric cancer AGS cells through suppressing MAPK and NF-kappaB signal pathways. Anticancer Res 30: 2135-2143, 2010.
35. Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT and Grant S: The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol 151: 70-83, 2010.
36. Terada Y, Nakashima O, Inoshita S, Kuwahara M, Sasaki S and Marumo F: Mitogen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-p38K and MKK1-MAPK. Nephrol Dial Transplant 1: 45-47, 1999. (Pubitemid 29041837)
37. Taylor JL, Szmulewitz RZ, Lotan T, Hickson J, Griend DV, Yamada SD, Macleod K and Rinker-Schaeffer CW: New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett 272: 12-22, 2008.